ACTREC

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
Thursday, March 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."

ACTREC Researchers Show Cancer Treatments May be Promoting its Spread

Retrieved on: 
Thursday, March 28, 2024
Research, Education, ACTREC, Glomus tumor, Neoplasm, DNA, Mouse, PLOS One, Radiation, Protein, Treatment, PLOS, Blood, Lymphatic system, Metastasis

MUMBAI, India, March 28, 2024 /PRNewswire/ -- Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing metastasis remains a major goal in oncology.

Key Points: 
  • In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis.
  • Their findings, published in PLOS One result from experiments in mice grafted with human breast cancer cells (xenografts) to induce cancer.
  • Prof. Mittra concludes,"Future long-term experiments should explore whether cfChP-deactivating agents given concurrently with anti-cancer treatments could help prevent metastatic spread.
  • When used as adjuncts to cancer treatment, these agents would have the added advantage of preventing some of the toxic side effects of chemotherapy and radiotherapy."

Indian Researchers from ACTREC Discover Novel Therapeutic Agent for a Host of Diseases

Retrieved on: 
Tuesday, January 17, 2023
Neurodegeneration, Cell, Fatality, Atomic energy, Metastasis, DNA damage (naturally occurring), Chromosome, Chromatin, Cytokine, Acral lentiginous melanoma, DNA, Copper, Resveratrol, Surgical oncology, Diarrhea, Treatment, Copper toxicity, Genetically modified bacteria, Emeritus, DNA repair, Protein, Patient, Saliva, Sepsis, Mouse, Bone marrow, Transplant, Research, Vomiting, Serum, Tata Memorial Centre, Inflammation, Incidence, Alzheimer's disease, RESCU, Department of Atomic Energy, ACTREC, Docetaxel, Translational research, Vaccine, TMC, Cancer

MUMBAI, India, Jan. 17, 2023 /PRNewswire/ -- Chromatin comprises a complex mixture of DNA and proteins and forms the structural basis of chromosomes in the cellular nuclei. When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system. Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes. Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer. Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

Key Points: 
  • When cells die, they release cell-free chromatin particles or "cfChPs" into the circulatory system.
  • Emerging evidence indicates that cfChPs exert toxic effects by damaging the DNA of healthy cells and activating pro-inflammatory processes.
  • Researchers from the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), India, have recently demonstrated therapeutic benefits of a pro-oxidant mixture of resveratrol and copper, R-Cu, in patients undergoing chemotherapy for advanced gastric cancer .
  • Combining R with Cu (R-Cu) leads to the generation of free oxygen radicals which can inactivate the offending cfChPs.

Curadev Pharma announces the formation of its Clinical Advisory Group

Retrieved on: 
Friday, December 23, 2022
Hospital, Patient, Dana–Farber Cancer Institute, ESMO, US, Joint Clinical Research Centre, CAG, Squamous cell carcinoma, Immune system, Tata Memorial Centre, Patent, University, NCCN, Society, Image, Precision medicine, CSO, Health, Lung cancer, FIH, ACTREC, DNA repair, DNA, Therapy, Cancer, Haematopoietic system, Medicine, Research, Pharmaceutical industry, Medical imaging

Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers.

Key Points: 
  • Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers.
  • Dr. Arjun Surya, CEO and CSO of Curadev said that, "We are honored to work with such an esteemed group of accomplished clinician researchers.
  • The expertise of these KOLs in the early stages of clinical development will be instrumental in unlocking the promise of CRD3874".
  • His areas of interest are hemato-oncology and bone marrow transplantation and he is a founder member of Indian Myeloma Group (IMAGe).